Homocysteine Serum Levels and Methylenetetrahydrofolate (MTHFR) C677T Genotype in Patients with Parkinson's Disease, with and without Levodopa Therapy _ Crimson Publishers


Homocysteine Serum Levels and Methylenetetrahydrofolate (MTHFR) C677T Genotype in Patients with Parkinson's Disease, with and without Levodopa Therapy by Eleonora DŽoljić* and Vladimir Kostić  in Degenerative Intellectual & Developmental Disabilities

Both methylenetetrahydrofolate (MTHFR) C677T genotype and levodopa treatment may give rise to elevated serum homocysteine levels in parkinsonian patients. We aimed to clarify the interplay of these factors in pathogenesis of Parkinson's disease (PD)-related hyperhomocysteinemia. Total serum levels of homocysteine (tHcy) and MTHFR C677T genotype were investigated in levodopa-treated and -untreated parkinsonian ("de novo”) patients, as well as in control healthy subjects matched by age and gender (N=83, 30 and 53, respectively). MTHFR C677T genotypes were equally distributed in PD patients and control subjects, the T allele homozygosity being observed in app. 12-17% cases.


For more open access journals in Crimson Publishers please click on link: https://crimsonpublishers.com/

For more articles in open access Disabilities journals please click on link: https://crimsonpublishers.com/didd/

Comments

Popular posts from this blog

The Ideological Basis of Stupidity: Journal of Intellectual and Developmental Disability: Crimson Publishers